Share on StockTwits

Cytosorbents Corp (NASDAQ:CTSO) Director Al Kraus sold 50,000 shares of Cytosorbents Corp stock in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $0.24, for a total transaction of $12,000.00. Following the sale, the director now directly owns 1,393,631 shares in the company, valued at approximately $334,471. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Cytosorbents Corp (NASDAQ:CTSO) opened at 0.2375 on Tuesday. Cytosorbents Corp has a 52 week low of $0.08 and a 52 week high of $0.35. The stock’s 50-day moving average is $0.23 and its 200-day moving average is $0.2. The company’s market cap is $71.4 million.

Cytosorbents Corp (NASDAQ:CTSO) last issued its quarterly earnings data on Monday, March 31st. The company reported ($0.01) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.01). Analysts expect that Cytosorbents Corp will post $-0.02 EPS for the current fiscal year.

A number of research firms have recently commented on CTSO. Analysts at Zacks reiterated an “outperform” rating on shares of Cytosorbents Corp in a research note on Friday, May 16th. They now have a $0.50 price target on the stock. Finally, analysts at Brean Capital raised their price target on shares of Cytosorbents Corp from $0.50 to $1.00 in a research note on Tuesday, April 1st. They now have a “buy” rating on the stock.

CytoSorbents Corporation is a development stage critical care focused company using blood purification to treat life-threatening illnesses.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.